DAFTAR KEPUSTAKAAN. Universitas Sumatera Utara

Transcription

1 DAFTAR KEPUSTAKAAN Aaron Caplan: Prostate-Specific Antigen and the Early Diagnosis of Prostate Cancer: Pathology Patterns Reviews. Am J Clin Pathol Amer. Cancer Soc., Cancer Facts and Figures 2005 Atlanta, GA, American Cancer Society: Cancer Facts & Figures Atlanta, GA: American Cancer Society, American Cancer Society. Cancer Facts & Figures Atlanta, Ga: American Cancer Society; AUA Commentary. Prostate-specific antigen best practice policy. Oncology,2000; 14(2):267. Basso D, Fogar P, Piva MG, Novaglica F, Mazza S, Brayer-Galen T et al. Total PSA, free PSA/total PSA ratio and molecular PSA detection in prostate cancer; which is clinically effective and when? Urology 2000;55(5): Börgermann C, Loertzer H, Hammerer P, et al. [Problems, objective, and substance of early detection of prostate cancer]. Urologe A 2010 Feb;49(2): Carter BS, Bova GS, Beaty TH, et al: Hereditary prostate cancer: Epidemiologic and clinical features. J Urol 150:797, Carter HB, Epstein JI, Partin AW: Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. Urology 1999; 53: Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Adres R, et al., Longitudinal evaluation of prostate specific antigen levels in men with and without protate disease, JAMA (1992); 267:pp2,215-2,220. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men, J Urol. 1994; 151:

2 Chan JM, Gann PH, Giovannucci EL: Role of diet in prostat cancer development and progression. J Clin Oncol 2005;23(32): Christensson A, Bjork T, Nilsson O, Dahlen U, Matikainen M, Cockett ATK, et al. Serum prostate specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150: Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990; 194: Epstein Jl: Allsbrook WC, Jr, Amin MB, Egevad LL, ISUP Grading Commitee: The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005, 29: Gleason DF. Histologic grading of prostate cancer: a perspective. HumanPathology, 1992; 23(3):273.9 Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Path 1992;23: Gleason DF. Histologic grading of prostatic carcinoma.in: Bostwick DG (ed). Pathology of the Prostate.Churchill Livingstone: New York, 1990, pp Gleave ME, Hseih J, Wu H, Echenbach AC von, Chung LWK. Serum prostate specific antigen levels in mice bearing human prostate LNCaP. Tumors are determinated by tumor volume and endocrine and growth factors. Cancer Res 1992;52: Greenlee RT, Murray T, Bolden S, et al. Cancer satistics, CA Cancer J Clin. 2000;50:7-33. Hessels D, Verhaegh GW, Schalken JA, Witjes JA. Applicability of biomarkers in the early diagnosis of prostate cancer. Expert Rev Mol Diagn,2004; 4: HB Carter, JI Epstein, AW Partin. Influence of age prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. Urology 53(1): , 1999.

3 Jemal A, Siegel R, Ward E, et al. Cancer statistics, CA Cancer J Clin 2007; 57: Jemal A, Tiwari R C, Murray T, Ghafoor A, Ward E, et al. Cancer statistics, 2004, CA Cancer J. Clin. (2004); 54: pp Kim HL,Steinberg GD: New insights and candidate genes and their implication for care of patient with hereditary prostate cancer. Curr Urol Rep 1:9, Kirby R, Fitzpatrick J. Prostate-specific antigen testing for the early detection of prostate cancer. BJU Int, 2004; 94(7): Lilja H, Christensson A, Dahlěn U, Matikainen M-T, Nilsson O, Pettersson K, et al. Prostate-specific antigen in serum occurs predominantly in complex with α1-antichymotrypsin. Clin Chem 1991;37: Luderer AA, Chen YT, Soriano TF, Kramp WJ, Carlson G, Cuny C, et al. Measurement of the proportion of free to prostate specific antigen improves diagnostic performance of prostate specific antigen in the diagnostic gray zone of total prostate specific antigen. Urology 1995;46: Montironi R, Mazzucchelli R, Algaba F. Prostate-specific antigen as a marker of prostate disease. Virchows Arch. 2000;436: Moyad MA: Selenium and vitamin E supplements of prostate cancer: Evidence or embellishment? Urology 59:9,2002. Newcomer LM, Stanford JL, Blumenstein BA, Brawer Mk. Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, J Urol 1997; 158: Poel HG, Schalken JA, Debruyne FMJ. Image analisys and grading of prostate adenocarcinoma. W J Urol 1991;9: Radić S. Prostate cancer molecular staging. State of the Art in prostate and breast cancer treatment. European school of oncology. Advanced course. September, 2002, Education boo P

4 Sebo TJ, Bock BJ, Cheville JC, Lohse C,Wollan P, Zincke H. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. Journal of Urology, 2000; 163(1):174. Stenman U-H, Hakama M, Knekt P, Aromaa A, TeppoL, Leinonen J, Serum concentrations of prostate specific antigen and its complex with a 1- antichymotrypsin before diagnisis of prostate cancer, Lancet (1994);344:pp 1,594-1,598. Stenman U-H, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate specific antigen and α-antichymotrypsin is the major form of prostate specific antigen in serum of patients with prostatic cancer. Cancer Res 1991;51: ( SEER Stat Database: Incidence SEER 9 Regs Limited-Use, Nov 2006 Sub ( ), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2008, based onthe November 2007 submission. ( SEER StatDatabase: Mortality All COD, Public-Use With State, Total U.S. ( ), National CancerInstitute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2008.Underlying mortality data provided by NCHS ( ( Prevalence database: US Estimated Complete Prevalence Counts on 1/1/2005. National Cancer Institute, DCCPS, Surveillance Research Program, Statistical Research and Applications Branch, released April 2008, based on the November 2007 SEER data submission.

5 TA Stamey, N Yang, AR Hay, JE McNeal, FS Freiha, E Redwine. Prostatespecific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317: , Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, ParnesHL, Coltman CA Jr. Operating characteristics of prostate-specific antigen in menwith an initial PSA level of 3.0 ng/ml or lower. JAMA,2005; 294(1): Veličković Lj, Katić V, Tasić D, Kutlešić Č, Dimov D, ĐorĎević B et al. Prostate specific antigen (PSA) in neoplastic dan hiperplastic prostate tissue. Arch Oncol 2001;9(1): Walsh PC. Why make an early diagnosis of prostate cancer. J Urol 1990;147: Wilson S S, Crawford E d, Screening for prostate cancer, Clin. Prostate Cancer (2004); 3:pp WJ Catalona, DS Smith, TL Ratliff, KM Dodds, DE Coplen, JJ Yuan, JA Petros, Gl Andriole. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324: , Zickovic s. Correlation between prostate-specific antigen and histopathological difference of prostate carcinoma. Arch Oncol 2004; 12(3):